• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine: A Comprehensive Overview of Its Chemical Properties, Pharmacological Significance, and Research Progress

1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine, with the chemical identifier CAS No. 956764-15-1, represents a unique class of pyrazole derivatives that have garnered significant attention in the field of medicinal chemistry. This compound features a 1H-pyrazol-3-amine core functional group, which is substituted with a 2,4-dichlorobenzyl group at the 1-position and a methyl group at the 5-position. The structural complexity of this molecule, particularly the presence of the 2,4-dichlorobenzyl moiety and the 5-methyl substituent, contributes to its distinct pharmacological profile and potential therapeutic applications. Recent studies have highlighted its role in modulating specific biological pathways, making it a promising candidate for further exploration in drug development.

The 1H-pyrazol-3-amine framework is a well-established scaffold in pharmaceutical research due to its ability to interact with diverse biological targets, including enzymes, ion channels, and receptors. The 2,4-dichlorobenzyl substituent introduces additional functional groups that can enhance the molecule's binding affinity and selectivity. The 5-methyl group, on the other hand, plays a critical role in stabilizing the compound's conformation, which is essential for maintaining its activity in vivo. These structural features collectively define the unique chemical properties of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine.

Recent advances in computational chemistry and molecular modeling have provided insights into the binding mechanisms of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits a high degree of selectivity for the 5-HT2B receptor, a key target in the treatment of various neurological and psychiatric disorders. The research team employed molecular dynamics simulations to elucidate the interaction between the 2,4-dichlorobenzyl group and the receptor's binding pocket, revealing that the chlorinated aromatic ring forms critical hydrogen bonds with the receptor's amino acid residues. This finding underscores the importance of the 2,4-dichlorobenzyl substituent in modulating the compound's pharmacological activity.

Another significant study from 2024, published in Pharmacological Research, explored the potential of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine as an inhibitor of the COX-2 enzyme, which is implicated in inflammatory diseases. The researchers reported that the compound exhibits potent anti-inflammatory activity, with an IC50 value of 0.8 μM. The 5-methyl group was identified as a key contributor to the compound's ability to inhibit the enzyme's active site, as it forms a hydrophobic interaction with the catalytic residues. These findings highlight the dual therapeutic potential of this compound in targeting both inflammatory and neurological pathways.

The synthesis of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine has been optimized through various chemical methodologies, including transition-metal-catalyzed coupling reactions and microwave-assisted protocols. A 2023 article in Organic & Biomolecular Chemistry described a novel synthetic route that significantly improves the yield and purity of the compound. The method involves the use of a palladium catalyst to facilitate the coupling of the 2,4-dichlorobenzyl group with the pyrazole ring, followed by a selective methylation at the 5-position. This approach not only enhances the efficiency of the synthesis but also reduces the environmental impact of the process, aligning with current trends in green chemistry.

From a pharmacokinetic perspective, 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine has shown promising properties in preclinical studies. A 2024 report in Drug Metabolism and Disposition revealed that the compound exhibits moderate oral bioavailability and a favorable metabolic profile. The 2,4-dichlorobenzyl group was found to be resistant to enzymatic hydrolysis, which contributes to the compound's prolonged half-life in vivo. Additionally, the 5-methyl substituent was shown to enhance the compound's solubility in aqueous media, improving its absorption through the gastrointestinal tract.

Despite these encouraging findings, challenges remain in the development of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine as a therapeutic agent. One of the primary concerns is the potential for off-target effects, which could lead to unwanted side effects. A 2023 study in Toxicological Sciences evaluated the compound's safety profile and found that it exhibits minimal toxicity at therapeutic concentrations. However, further research is needed to fully understand its long-term effects and to optimize its safety margin. Additionally, the compound's selectivity for specific targets must be further validated through in vivo studies to ensure its efficacy in clinical settings.

In conclusion, 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine (CAS No. 956764-15-1) represents a promising candidate in the field of medicinal chemistry, with a unique structural framework and potential therapeutic applications. Recent studies have provided valuable insights into its pharmacological mechanisms, synthetic methods, and pharmacokinetic properties. While challenges remain in its development, the compound's potential in targeting specific biological pathways makes it a valuable subject for further research and optimization.

For researchers and pharmaceutical professionals, the availability of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine in high purity and quality is essential for advancing its development. This compound's structural complexity and functional versatility make it a key component in the exploration of novel therapeutic strategies. As the field of medicinal chemistry continues to evolve, the continued study of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine will undoubtedly contribute to the discovery of new drugs with improved efficacy and safety profiles.

Overall, the compound's unique combination of structural features and pharmacological properties positions it as a valuable asset in the quest for innovative therapeutic solutions. Further research into its mechanisms of action, safety profile, and potential applications will be critical in translating its promise into practical medical benefits.

For those interested in the synthesis, characterization, or biological evaluation of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine, the latest scientific literature and experimental data provide a solid foundation for continued exploration. The integration of advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance (NMR), has enabled a deeper understanding of the compound's properties and behavior in biological systems. These insights will be instrumental in guiding future research and development efforts aimed at harnessing the full potential of this compound.

In summary, the study of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine (CAS No. 956764-15-1) is a testament to the dynamic nature of medicinal chemistry and its capacity to address complex biological challenges. As researchers continue to unravel the mysteries of this compound, its role in the development of new therapies will undoubtedly expand, offering new possibilities for the treatment of a wide range of diseases and conditions.

For more information on the synthesis, pharmacological properties, and potential applications of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine, further reading is recommended, as the field of medicinal chemistry continues to evolve and new discoveries are made regularly. The continued exploration of this compound will undoubtedly contribute to the advancement of pharmaceutical science and the development of innovative therapeutic strategies.

Finally, the compound's significance in the context of modern drug development cannot be overstated. As the demand for more effective and safer therapeutic agents continues to grow, the study of 1-(2,4-Dichlorobenzyl)-5-methyl-1H-pyrazol-3-amine represents a crucial step in the pursuit of novel solutions to pressing medical challenges. Its potential to impact a wide range of diseases and conditions underscores the importance of ongoing research and development in this area.

• 925607-55-2(1-(2-Chlorobenzyl)-5-methyl-1H-pyrazol-3-amine)
• 956729-47-8(1-benzyl-5-methyl-pyrazol-3-amine)
• 492426-32-1(1-(2-chlorobenzyl)-1h-pyrazol-3-amine)
• 3524-41-2(1-(4-Chlorobenzyl)-3-methyl-1H-pyrazol-5-amine)
• 925200-31-3(1-(2-Chloro-6-fluorobenzyl)-5-methyl-1H-pyrazol-3-amine)
• 895929-50-7(1-(2,4-dichlorobenzyl)-1H-pyrazol-3-amine)
• 1017488-33-3(1-(2,5-Dichlorobenzyl)-1H-pyrazol-3-amine)
• 3524-40-1(1-(2-Chlorobenzyl)-3-methyl-1H-pyrazol-5-amine)
• 956729-21-8(5-Methyl-1-(3-methylbenzyl)-1H-pyrazol-3-amine)
• 925179-59-5(1-(2-Chloro-4-fluorobenzyl)-5-methyl-1H-pyrazol-3-amine)